Abstract. Transcriptional co-activator with PDZ-binding motif (TAZ) is a transcriptional co-activator which binds to a variety of transcription factors. An increasing number of studies have provided evidence that TAZ may be a positive regulator of cell proliferation and tumorigenesis. To reveal the underlying mechanisms by which TAZ controls these cellular processes, the present study used lentivirus expression system, flow cytometry, immunofluorescence and subcutaneous xenograft assays. The present study demonstrated that TAZ promoted and was indispensable for neuroblastoma cell proliferation and tumorigenesis. Additional mechanistic assays revealed that the downregulation of TAZ induced cell cycle arrest in the G1 phase, which may be mediated through the inhibition of cyclin E2 expression. These findings indicated that TAZ may serve as a potential neuroblastoma therapeutic target.
Introduction
Neuroblastoma is a common, malignant childhood tumor of the sympathetic nervous system that originates from primordial neural crest cells. Neuroblastoma is affected by age, localization and the degree of differentiation, and it exhibits marked variations in clinical presentation and biological characteristics (1, 2) . Certain cases of neuroblastoma spontaneously regress to benign neuroblastoma, whereas others are difficult to cure and have poor prognoses (3) (4) (5) (6) . Despite significant improvements in the treatment of early-stage neuroblastoma and infantile neuroblastoma over past decades, the mechanism of neuroblastoma tumorigenesis remains unclear.
Transcriptional co-activator with PDZ-binding motif (TAZ) is a transcriptional co-activator which has been reported to bind to a variety of transcription factors, including thyroid transcription factor-1, T-Box 5 and paired box 3 (7) . TAZ functions as a major effector of the Hippo pathway and is involved in tissue homeostasis regulation, regeneration and tumorigenesis. TAZ has been reported to be a positive regulator of cell proliferation and tumorigenesis of breast cancer (8) . A previous study also proposed that TAZ is involved in cell proliferation and in the tumorigenesis of neuroblastoma (9) , however, the potential molecular mechanisms have not been sufficiently elucidated.
In the present study, TAZ was demonstrated to be associated with neuroblastoma cell proliferation and tumorigenesis, and insight was gained into the underlying mechanisms, which may promote the development of potential neuroblastoma treatments.
Materials and methods
Cell culture. The human neuroblastoma cell line BE(2)-C was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and was cultured in DMEM/F12 ( Lentiviral production and infection. The lentiviral constructs pCDH-CMV-EF1-TAZ and pCDH-CMV-EF1-cop green fluorescent protein (GFP) (System Biosciences, Inc., Palo Alto, CA, USA) were used for overexpression assays. For the downr eg u lat ion of TA Z , t he lent iv i r a l c on st r uct s pLK0.1-puro-GFP-specified small interfering RNA (GFPsi) and pLK0.1-puro-TAZ-specified small interfering RNA (TAZsi; TAZsi#1: CCGGCGGACTTCATTCAAGAGGAA TCTCGAGATTCCTCTTGAATGAAGTCCGTTTTTG, TAZsi#2: CCG GCTGTACGAGCTCATCGAGAAGCTCGA GCTTCTCGATGAGCTCGTACAGTTTTTG) were mixed with 0.5 µg pLP1, pLP2 and pLP/VSVG (Invitrogen; Thermo Fisher Scientific, Inc.) plasmids and transfected into 293FT packaging cells (Invitrogen; Thermo Fisher Scientific, Inc.) using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Inc.). Virus-containing supernatants were harvested and titered, passed through a 0.45 µm filter and used to infect target cells. Subsequent to the final round of infection, target cells were grown in the presence of 2 µg/ml puromycin (Thermo Fisher Scientific, Inc.), and drug-resistant cells were harvested. Target cells were infected with two rounds in total, for 24 h at a time.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Cells were harvested and lysed with TRIzol (Thermo Fisher Scientific, Inc.) for total RNA purification. RNA was reverse transcribed into cDNA using SuperScript II reverse transcriptase (Thermo Fisher Scientific, Inc.). The buffer, dNTPs and oligo (dT) were purchased from Thermos Fisher Scientific, Inc. TAZ mRNA transcripts were measured using RT 2 SYBR-Green/fluorescein PCR master mix (Takara Biotechnology Co., Ltd., Dalian, China). RT-qPCR reactions were performed in triplicate using an iQ5 Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Individual values were normalized against those of a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control. The GAPDH RT-qPCR primer sequences were as follows: 5'-GTC TCC TCT GAC TTC AAC AGC G-3' (sense) and 5'-ACC ACC CTG TTG CTG TAG CCA A-3' (antisense). The TAZ RT-qPCR primer sequences were as follows: 5'-GGG TTA GGG TGC TAC AGT GTC C-3' (sense) and 5'-GGG TCT GTT GGG GAT TGA TG-3' (antisense). The conditions for PCR were 95˚C for 30 sec followed by 42 cycles of 95˚C for 10 sec and 60˚C for 30 sec. Relative mRNA expression levels were determined using the 2 -ΔΔCq method (10) . Cell viablity analysis. BE(2)-C or SK-N-AS cells were seeded onto 96-well culture plates with 800 cells/well, and the cell viability was determined by MTT (Sigma-Aldrich; Merck KGaA) analysis. Briefly, cells in each well were incubated with 20 µl MTT reagent in 100 µl medium (BE(2)-C in DMEM/F12, SK-N-AS in DMEM) at 37˚C for 2 h. The supernatant was then removed and 150 µl dimethyl sulfoxide was added to dissolve the blue crystals. The absorbance was measured at a wavelength of 560 nm using a microplate reader (Model 550; Bio-Rad Laboratories, Inc.). Cell cycle analysis. A total of 1x10 6 cells were collected by centrifugation at 1,000 x g in 4˚C for 5 min, washed twice with ice-cold PBS, fixed with 70% ethanol and stained with 20 µg/ml propidium iodide (Invitrogen; Thermo Fisher Scientific, Inc.). The samples were analyzed by flow cytometry using a BD FACSVerse flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), and the data were analyzed with BD CellQuest Pro software version 5.1 (BD Biosciences).
5-bromo-2-deoxyuridine (
Colony formation assay. The oncogenic potential was evaluated in vitro by determining the colony-forming ability in soft agar cultures. For the lower layer, 1 ml of 0.6% agarose (Thermo Fisher Scientific, Inc.) in growth medium was added to each well of a 6-well plate. For the upper layer, 2 ml of 0.3% agarose in growth medium containing 1x10 3 cells was added to each well. Following ~3 weeks of culture at 37˚C, 6 fields of the colonies were counted using a Nikon 80i light microscope.
In vivo tumorigenesis assay. For the in vivo tumor formation study, 5x10 6 cells per injection point were subcutaneously injected into the lateral backsides of 6 (5 weeks old; 18-22 g) non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) female mice (Beijing Vital River Laboratory Animal Technology Co., Ltd., China) and housed in an SPF room that was maintained at a constant temperature (20-25˚C) and humidity (45-55%) with a 12-h light:dark cycle. The mice were fed a commercial diet (Beijing Vital River Laboratory Animal Technology Co., Ltd.) and sterile water ad libitum. GFPsi and TAZsi SK-N-AS cells were implanted in the left and right side of each mouse, respectively. Tumor growth was monitored by measuring the volume with calipers (volume= (π/6) x length x width 2 ). Following ~2 weeks, the mice were sacrificed and the tumors were harvested and weighed.
All mice were raised under specific pathogen-free conditions. Experimental procedures and animal welfare were conducted according to the Guide for the Care and Use of Laboratory Animals (Ministry of Science and Technology of China, 2006) and were approved by the Animal Ethics Committee of Southwest University (Chongqing, China).
Statistical analysis.
All observations were confirmed by performing at least three independent experiments. Quantitative data were expressed as the mean ± standard deviation. Two-tailed Student's t-tests were performed using GraphPad Prism (version 6.0; GraphPad Software, Inc., La Jolla, CA, USA) for paired samples. P<0.05 was considered to indicate a statistically significant difference.
Results

TAZ is commonly expressed in neuroblastomas.
To investigate the expression profile of TAZ in neuroblastomas, four neuroblastoma cell lines, SK-N-AS, BE(2)-C, SK-N-DZ and SK-N-F1, were analyzed using western blotting and RT-qPCR. TAZ was detected in all four cell lines, among which the TAZ expression level was highest in SK-N-AS, moderate in SK-N-DZ and SK-N-F1 and lowest in BE(2)-C (Fig 1) . Western blot analysis and RT-qPCR demonstrated consistent results, indicating that TAZ is commonly expressed in neuroblastoma cell lines.
Overexpression of TAZ promotes cell proliferation and self-renewal in neuroblastoma BE(2)-C cells.
To explore the potential function of TAZ in regulating cell growth and proliferation in neuroblastoma, TAZ was overexpressed in the BE(2)-C cell line. The overexpression efficiency was verified at the mRNA and protein levels ( Fig. 2A and B, respectively) . Growth curves and BrdU staining assays were employed to examine the cell viability and proliferation abilities of BE(2)-C cells with and without TAZ overexpression. The results revealed that the TAZ-overexpressing BE(2)-C cells exhibited significant increases in viability and BrdU-positive signals ( Fig. 2C and D, respectively) , indicating that the overexpression of TAZ enhanced BE(2)-C cell viability and proliferation.
Furthermore, colony formation ability was detected using soft agar assays to evaluate the oncogenicity of cells in vitro. TAZ-overexpressing BE(2)-C cells formed significantly more colonies compared with the control (Fig. 2E) , indicating an increased cell self-renewal ability and in vitro oncogenicity following overexpression of TAZ.
Downregulation of TAZ inhibits cell proliferation and self-renewal in neuroblastoma SK-N-AS cells.
Since the SK-N-AS cell line had the highest TAZ expression, TAZ knockdown was performed in this cell line. Two lentiviral plasmids expressing small interfering RNA sequences against TAZ were used, and the two succeeded in knocking down TAZ in SK-N-AS cells (Fig. 3A and B) . A marked decrease in cell number was observed under a 20x Nikon 80i light microscope following knockdown of TAZ (Fig. 3C) . In addition, the MTT and BrdU staining assays revealed that cell viability and proliferation were significantly (P<0.01; P<0.001) inhibited in the TAZsi group compared with the GFPsi group ( Fig. 3D and E, respectively) .
The colony formation abilities of SK-N-AS cells with or without TAZ downregulation were also examined. The results demonstrated that the TAZsi group formed fewer colonies compared with the control group (Fig. 3F) , indicating that the self-renewal and clonogenic abilities of the TAZ-silenced SK-N-AS cells were weakened by knocking down TAZ. These results indicated that TAZ was necessary for neuroblastoma cell proliferation and self-renewal.
Downregulation of TAZ induces cell cycle arrest in the G1 phase.
To gain additional insights into the association between TAZ and cell proliferation, the cell cycle status of SK-N-AS cells was examined by flow cytometry. Following TAZ downregulation, SK-N-AS cells exhibited a marked increase in G1 phase and a significant decrease in the S phase (Fig. 4A) . Fig. 4B depicts the statistical data. Furthermore, the cell cycle-associated protein levels of several cyclins and cyclin-dependent kinases were examined to elucidate the molecular mechanism underlying cell cycle arrest. Western blot analysis results revealed that the inhibition of cyclin E2 expression was associated with TAZ knockdown, and that there were no evident changes in the expression of other cyclins or CDKs (Fig. 4C) . Cyclin E2 is known as an essential protein for the cell cycle G1/S transition, and its expression peaks at the late G1 and early S phase. The present data indicated that cell cycle arrest in the G1 phase, induced by TAZ downregulation, may be mediated through the inhibition of cyclin E2 expression.
TAZ is required for tumorigenesis, and TAZ knockdown affects cell cycle progression in vivo.
As TAZ was essential for the clonogenic ability of neuroblastoma cells in vitro (Figs. 2E and 3F) , the in vivo tumorigenicity of TAZ knockdown and control SK-N-AS cells was investigated. A subcutaneous xenograft mouse model was used to examine the effect of TAZ downregulation on tumorigenesis in NOD/SCID mice. The volume and weight of the TAZsi tumors were significantly decreased compared with the GFPsi group (Fig. 5A and B, respectively) . Furthermore, western blot analysis of the xenograft tumors revealed that the expression patterns of the cyclins and CDKs were similar to those of the TAZsi SK-N-AS cells. Cyclin E2 was visibly decreased, indicating cell cycle arrest in the TAZsi tumors (Fig. 5C ). 
Discussion
The transcriptional co-activator TAZ has been reported to be associated with carcinogenesis in multiple human malignant cancers, including breast cancer, ovarian cancer, lung cancer and hepatocellular carcinoma (11) (12) (13) (14) . TAZ functions as an oncogene and regulates various biological processes, including cell proliferation, tumorigenesis, invasion, metastasis and chemoresistance (15) (16) (17) (18) (19) (20) (21) (22) . However, the molecular mechanism underlying TAZ-mediated regulation of cell proliferation and tumorigenesis is unclear and requires additional study. The results of the present study demonstrated that the upregulation of TAZ in BE(2)-C, a neuroblastoma cell line with low TAZ expression, promoted cell proliferation and self-renewal in vitro. Furthermore, it was revealed that the downregulation of TAZ in SK-N-AS (a neuroblastoma cell line with high TAZ expression) suppressed cell proliferation and self-renewal in vitro and tumorigenesis in vivo. These data indicated that TAZ is essential for sustaining neuroblastoma cell proliferation and tumorigenesis.
Cell cycle progression is associated with cell proliferation and tumorigenesis, and cyclins and CDKs are key proteins that regulate cell cycle progression. Data from the present mechanistic study demonstrated that the downregulation of TAZ in SK-N-AS cells induced cell cycle arrest in the G1 phase and decreased the expression of cyclin E2, which is involved in The expression patterns of cyclins and CDKs in the xenograft tumors were examined by western blot analysis. GAPDH was used as the loading control. For all the knockdown experiments, GFPsi was used as the control. The data were analyzed using two-tailed Student's t-tests and are presented as the mean ± standard deviation; n=3. *** the cell cycle G1/S transition. Western blot analysis of in vivo xenograft tumors produced the same results. The present data provided evidence that TAZ is involved in the control of cell cycle progression by regulating the expression of cyclin E2 in neuroblastoma.
In conclusion, the present data revealed that TAZ is essential for sustaining neuroblastoma cell proliferation and tumorigenesis, and that TAZ knockdown in neuroblastoma induces cell cycle arrest in the G1 phase, as well as cyclin E2 downregulation. The present findings indicated that TAZ may serve as a potential therapeutic target in neuroblastoma.
